NOVN Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Jul 2023 @ 16:00):

Stats
Today's Volume	6.93M
Average Volume	1.04M
Market Cap	2.64M
EPS	$0 ( 2024-03-28 )
Next earnings date	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.112
ATR14	$0.103 (183.93%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-27	Sanders Machelle	Sell	11 553	Common Stock
2023-06-06	John A. Donofrio	Buy	85 000	Restricted Stock Units
2023-06-06	Gay John M.	Buy	200 000	Restricted Stock Units
2023-06-07	Gay John M.	Buy	65 000	Common Stock
2023-06-06	Gay John M.	Buy	65 000	Restricted Stock Units

INSIDER POWER
61.00
Last 97 transactions
Buy: 4 746 863 \| Sell: 340 227

Volume Correlation

Long: -0.41 (neutral)

Short: -0.55 (weak negative)

Signal:(24.752) Neutral

Novan Inc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Novan Inc Correlation - Currency/Commodity

0.65
( weak )

0.62
( weak )

0.00
( neutral )

-0.10
( neutral )

-0.32
( neutral )

-0.82
( strong negative )

Novan Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$0

Q1	2023
Revenue:	$3.00M
Gross Profit:	$1.71M (57.11 %)
EPS:	$-0.540

Q4	2022
Revenue:	$10.47M
Gross Profit:	$7.35M (70.19 %)
EPS:	$1.210

Q3	2022
Revenue:	$5.10M
Gross Profit:	$3.66M (71.75 %)
EPS:	$-0.0998

Financial Reports:

No articles found.

Novan Inc

Novan, Inc., a pre-commercial nitric oxide-based pharmaceutical company, focuses on dermatology and anti-infective therapies. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. Novan, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.